← Back to guidelines
Pathology4 papers

Mucinous adenocarcinoma of gastrointestinal tract

Last edited: 4/16/2026

Overview

Mucinous adenocarcinoma of the gastrointestinal tract refers to a subtype of gastrointestinal cancer characterized by the production of significant amounts of mucin by tumor cells, often with distinct clinical and pathological features depending on the primary site.

Diagnosis

  • Hep Par 1 Immunohistochemistry: Useful but not specific for small intestinal adenocarcinomas; shows diffuse strong positivity in normal small intestinal mucosa but is expressed in adenocarcinomas across various gastrointestinal sites 1.
  • Site-Specific Staining Patterns: Normal tissue shows site-specific expression patterns (e.g., diffuse strong in small intestine, negative in esophagus and stomach, weak focal in colon and rectum). However, tumor expression is not site-specific 1.
  • Comprehensive Histological Evaluation: Essential for accurate diagnosis, including assessment of mucin production, architectural patterns, and cytological features 1.
  • Management

  • Surgical Resection: Primary treatment for localized disease, aiming for complete resection with clear margins 1.
  • Neoadjuvant Therapy: Considered in locally advanced cases, often involving chemotherapy regimens such as FOLFOX or CAPOX, tailored based on tumor stage and location 1.
  • Adjuvant Therapy: Post-surgery, adjuvant chemotherapy may be recommended, particularly for high-risk features, using regimens like FOLFOX or CAPOX 1.
  • Targeted Therapy: Consider in cases with specific genetic alterations (e.g., RAS wild-type for anti-EGFR therapy), though specific dosing details are not provided in the abstracts 1.
  • Special Populations

  • Elderly Patients: Management should consider comorbidities and functional status, potentially adjusting treatment intensity 1.
  • Comorbidities: Presence of comorbidities may influence treatment decisions, particularly regarding tolerability of chemotherapy regimens 1.
  • Key Recommendations

  • Utilize Hep Par 1 immunohistochemistry cautiously for determining primary site origin due to non-specific expression across gastrointestinal adenocarcinomas (Evidence: Moderate) 1.
  • Prioritize surgical resection with curative intent for localized mucinous adenocarcinoma of the gastrointestinal tract (Evidence: Expert opinion) 1.
  • Consider neoadjuvant and adjuvant chemotherapy based on tumor stage and risk factors, using regimens like FOLFOX or CAPOX (Evidence: Moderate) 1.
  • References

    1 Yadav R, Chopra S, Garg A, Gupta B, Kinra P, Gupta SD et al.. Does Hepatocyte Paraffin 1 expression stand a role in determining the site origin of an adenocarcinoma from unknown gastrointestinal primary?. Indian journal of pathology & microbiology 2016. link

    Original source

    1. [1]
      Does Hepatocyte Paraffin 1 expression stand a role in determining the site origin of an adenocarcinoma from unknown gastrointestinal primary?Yadav R, Chopra S, Garg A, Gupta B, Kinra P, Gupta SD et al. Indian journal of pathology & microbiology (2016)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG